Research and Markets: Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis is Essential Reading for Those in the P

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/6dcf80/triple_analysis_b) has announced the addition of the "Triple Analysis: Breast Cancer, Lung Cancer and Angiogenesis" report to their offering.

This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.

This part is based on the following publication: Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Part II: Lung Cancer The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). This report part extensively analyses 182 identified targets of lung cancer drugs, organized into 173 drug target strategies, and assesses them in lung cancer.

This part is based on the following publication: Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

Part III: Angiogenesis The angiogenesis report part comprises defined and up to date development strategies for 239 drugs affecting angiogenesis in oncology within the portfolio of 148 investigators, from Preclinical to Marketed. This report part extensively analyses 174 identified targets of angiogenesis affecting drugs, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

This part is based on the following publication: Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drugs properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

  • Part I: Breast Cancer
  • 6 Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets) 33-376
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs) 377-441
  • 8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 442-488
  • 9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators) 489-891
  • 11 Drug Index 893
  • 12 Company Index 905
  • Figures: Includes 7 Figures
  • Tables: Includes 274 Tables
  • Total Number of Pages: 913
  • Part II: Lung Cancer
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (182 Drug Targets) 31-323
  • 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? (173 Drug Target Strategies and 283 Drugs) 324-368
  • 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound (7 Different Compound Strategies) 369-419
  • 9 Selecting a Sub-Indication of Lung Cancer for Drug Development 420-462
  • 10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator (167 Investigators) 463-751
  • 12 Drug Index 753
  • 13 Company Index 761
  • Figures: Includes 13 Figures
  • Tables: Includes 227 Tables
  • Part III: Angiogenesis
  • 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (174 Drug Targets) 39-366
  • 7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167 Drug Target Strategies and 239 Drugs) 367-437
  • 8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies) 438-485
  • 9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology (64 Cancer Indications) 486-643
  • 10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148 Investigators) 644-1211
  • 11 Drug Index 1213
  • 12 Company Index 1221
  • Figures: Includes 7 Figures
  • Tables: Includes 300 Tables

For more information visit http://www.researchandmarkets.com/research/6dcf80/triple_analysis_b



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Ireland

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.